Management of Severe Pulmonary Embolism

Initial Assessment and Definition of Severe Pulmonary Embolism

The American College of Chest Physicians recommends that severe pulmonary embolism be defined by the presence of hemodynamic instability with hypotension (systolic blood pressure <90 mmHg) or cardiogenic shock, which is associated with a high risk of early mortality and requires urgent intervention 1, 2
The assessment of right ventricular dysfunction using bedside echocardiography is crucial when computed tomography is not immediately available 3

The American College of Chest Physicians recommends that anticoagulation be initiated without delay, even before confirming the diagnosis by imaging in hemodynamically unstable patients 2
Unfractionated heparin (UFH) is the anticoagulant of choice in severe pulmonary embolism due to its short half-life and immediate reversibility 1, 2
The initial dose is a bolus of 5,000-10,000 units followed by a continuous infusion of 400-600 units/kg/day (or 30,000-40,000 units/24 hours) 4
The activated partial thromboplastin time (APTT) should be maintained at 1.5-2.5 times the control value, measured 4-6 hours after initiating treatment 4

The American College of Chest Physicians recommends that systemic thrombolysis be administered immediately to all patients with pulmonary embolism and hypotension who do not have a high risk of bleeding 1, 2
Alteplase (rtPA) is the preferred agent with a lower risk of hypotension and systemic symptoms compared to streptokinase 4
The dose is 0.6 mg/kg over 15 minutes (maximum 50 mg) or 100 mg over 2 hours 4

The American Thoracic Society recommends administering high-flow supplemental oxygen to correct hypoxemia 4, 2
Administering colloids while monitoring central venous pressure, maintaining high right atrial pressure (15-20 mmHg) to ensure maximum right ventricular filling 4
Avoiding diuretics and vasodilators as they may worsen cardiovascular collapse 4
Avoiding opioids in patients with imminent cardiovascular collapse due to their vasodilatory effect 4
Correcting systemic hypotension to prevent progression of right ventricular failure 2

If there are contraindications to thrombolysis, failure of thrombolytic treatment, or shock that will likely cause death before thrombolysis takes effect, consider catheter-assisted thrombus removal if experience and resources are available 1, 5
Surgical pulmonary embolectomy may be considered if there are contraindications to thrombolysis, failure of thrombolysis or catheter, or imminent shock 1, 5
Extracorporeal membrane oxygenation (ECMO) may be considered in extreme cases 5

After hemodynamic stabilization, continue heparin until adequate anticoagulation is achieved with warfarin 4
Warfarin can be initiated as soon as the diagnosis is confirmed, with an international normalized ratio (INR) target of 2.0-3.0 6
The minimum duration of anticoagulation is 3 months 1, 6, 7
For unprovoked pulmonary embolism, consider extended anticoagulation after 3 months if the risk of bleeding is low or moderate 6

Unfractionated heparin (UFH) administered by intravenous infusion is the only anticoagulant considered safe in end‑stage renal disease for high‑risk pulmonary embolism and allows rapid reversal if bleeding occurs. [8][9]10
Low‑molecular‑weight heparin (LMWH) is contraindicated when creatinine clearance is < 30 mL/min because of drug accumulation and a markedly increased bleeding risk. [8][11][12][9]10
Direct oral anticoagulants (DOACs) are not recommended in patients with end‑stage chronic kidney disease or on dialysis due to the absence of robust trial data and an uncertain risk‑benefit profile. 13
UFH is preferred because it has a short half‑life, is reversible with protamine sulfate, and is cleared hepatically rather than renally. [9][10]

Therapeutic UFH monitoring should target an activated partial thromboplastin time (aPTT) of 1.5–2.5 × the control value. 12
In patients with multiple high‑bleeding‑risk features (e.g., end‑stage renal disease, metastatic cancer, prolonged immobility), the aPTT should be kept at the lower end of the therapeutic range (1.5–2.0 × control) to mitigate bleeding. 12

Warfarin is the sole long‑term anticoagulant option for patients with CKD stage 5 when LMWH or DOACs are unsuitable. [13][8]
Warfarin can be initiated early (as early as day 1) while UFH is continued. 8
The therapeutic INR target for warfarin is 2.0–3.0. [13][12]
UFH should be maintained until the INR is ≥ 2.0 for at least two consecutive days before stopping UFH. 12

LMWH may be used on a case‑by‑case basis with anti‑Xa level monitoring, employing reduced dosing to achieve peak anti‑Xa concentrations of 0.5–1.5 IU/mL. [8][11]
Enoxaparin dose adjustment: 1 mg/kg subcutaneously once daily (instead of twice daily) for CrCl < 30 mL/min, with mandatory anti‑Xa monitoring. 11
Dalteparin monitoring: obtain peak anti‑Xa 4–6 hours after the third or fourth dose, targeting 0.5–1.5 IU/mL. 11

A minimum of 3 months of therapeutic anticoagulation is required for cancer‑associated pulmonary embolism. [14][10]
Extended anticoagulation is strongly recommended for as long as the malignancy remains active, given the persistent thrombotic risk. [14][10]
Patients should undergo monthly reassessment of bleeding complications, cancer progression, and ongoing need for anticoagulation. 15

Do not use standard‑dose LMWH in CKD stage 5 without anti‑Xa monitoring, as this leads to dangerous drug accumulation and bleeding. [8][11][9][10]
Do not prescribe DOACs (apixaban, rivaroxaban, edoxaban, dabigatran) in end‑stage renal disease; they are contraindicated. [13][8]
Do not use fondaparinux in severe renal impairment (CrCl < 30 mL/min) because it is renally cleared. [14][15]
Do not discontinue anticoagulation at 3 months in patients with active metastatic cancer; continued therapy is indicated. [14][10]